Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
Clinical trial NCT06389422 · RECRUITING
Trial details
- NCT number
- NCT06389422
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-01
- Primary completion
- 2026-04-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.